🍄 The New Health Club #39 - Busy Times Ahead With Psytech and Dr. Deborah Mash on our YouTube Show!
Busy times at the New Health Club. First up we have PSYTECH, the amazing psychedelic conference from Israel is coming to you next Tuesday, October 27th! And yes, it’s FREE! Join us LIVE tuesday, between 2-3pm CET.
PSYTECH is a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Join us at the global dialogue on the future of psychedelic medicine and innovation!
The summit will cater to thousands of virtual attendees as well as live guests at select city hubs across four continents.
Aaaand, we are proud sponsors of this upcoming FREE PsyTech Virtual Summit
Aaaand we will be hosting the Berlin chapter and bringing you some really exciting content, all in collaboration with Factory Berlin. It makes total sense to stick together and share our communities, since we’re all so interested in micro dosing anyway ;)
We have two amazing panels for you. I talk to Christian Angermayer (ATAI Lifesciences) and Graham Boyd (Dr. Bronner’s) about psychedelics in 2021 and the I’ll chat to Benjamin Maack, author and Spiegel editor about his book “Wenn das noch geht, kann es nicht so schlimm sein” which in English means "If it still works, it can't be that bad" (Suhrkamp Verlag) about depression, psychiatry and the “normal life” The book is incredible, a quick glimpse into a life, that could be very different, if psychedelic therapy was simply available to everyone.
We also have “Miss Ibogaine” Deborah Mash on the New Health Club YouTube Show, who will also be speaking at Psytech!
Miami-based Deborah Mash is one of the world’s foremost experts on the hallucinogenic drug Ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing Ibogaine and its active metabolite Noribogaine for the treatment of opioid use disorder. Most recently, DemeRx partnered with ATAI Life Sciences—a global biotech platform with a special focus on psychedelic medicine—to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around Ibogaine, DemeRx and ATAI will submit clinical trial applications for a Phase II study in opioid-dependent patients.
Deborah is fascinating. We talk about how cocaine was “flooding” Miami and how that left a trail of addicts with no hope for any help. This inspired Deborah to start looking into Ibogaine as a treatment, how Ibogaine can make you review your life and change it for good, and why the substance feels like a “lucid dream”.
by Ewan Waddell.
In psychedelic study news: Sansero Life Sciences recently announced a new partnership with the University of Toronto to study the effects of low-dose psilocybin on mental health conditions such as depression and anxiety.
Why it’s important: The clinical research into microdosing has been limited, with much of the supporting voices coming from anecdotal accounts. But clinical evidence is king, so this new partnership is a positive step forward.
In psychedelic legality news: A panel discussion titled “Can Psychedelics Help Save America?” is to be held at Harvard Law School this coming Wednesday (which you can watch online!). The discussion seeks to address questions like: Can psychedelics benefit those not helped by modern medicine? Could they help political rivals find common ground and work together to build a better future? And more.
Why it’s so important: Since the days of Timothy Leary—half a century ago—the philosophical and spiritual study of psychedelics has been exiled from the Ivy League Campuses of the US. And whilst these compounds are still Schedule 1, the dissolution of stigma from which this panel discussion emerges represents the kind of marked shift in public perception that foreshadows real, societal change—and that might be just what we need.
In study news: New research out of the Complutense University of Madrid discovered that in mice, Ayahuasca can contribute to the formation of new neurons.
What this means: Well of course it’s early doors, but this line of therapeutic research may pave the way for new approaches to treating degenerative neurological diseases in humans such as Alzheimers and Parkinsons.
In MDMA-therapy news:MAPS recently published a peer-reviewed study that proves how MDMA-assisted psychotherapy to treat PTSD is “remarkably cost-effective compared to currently available treatments”. Their findings estimate that if MDMA-assisted psychotherapy was made available to even just 1,000 PTSD patients, the public healthcare costs would reduce by $103.2 million over 30 years.
Why aren’t things changing?: They are (in large part thanks to Rick Doblin and MAPS), however, effecting widespread healthcare changes is a slow and expensive process. The momentum is growing though, and if you’d like to help it speed up, you can donate here.
Until next time.
AP